DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.

Author(s): Papadimitriou CA, Kalofonos H, Zagouri F, Papakostas P, Bozas G, Makatsoris T, Dimopoulos MA, Fountzilas G

Affiliation(s): Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece.

Publication date & source: 2009, Oncology., 77(3-4):212-6. Epub 2009 Sep 4.

Publication type: Clinical Trial, Phase II; Randomized Controlled Trial

OBJECTIVE: A randomized phase II trial was conducted to test whether the addition of gemcitabine to weekly docetaxel could improve the objective response rate and survival outcomes as second-line chemotherapy in patients with metastatic breast cancer who have failed a paclitaxel-containing regimen. METHODS: Patients were randomized to receive either weekly docetaxel 40 mg/m(2) (group A, n = 34) or the combination of weekly docetaxel 35 mg/m(2) with gemcitabine 600 mg/m(2) (group B, n = 41). Three consecutive weekly infusions followed by a 1-week rest period represented 1 chemotherapy cycle. RESULTS: The objective response rate was 18% and 27.5% in group A and B, respectively (p = 0.413). No statistically significant differences were demonstrated in terms of median overall survival and time to disease progression. The rate and grade 3 and 4 neutropenia were higher in group B (23 vs. 3%). CONCLUSIONS: The weekly administration of docetaxel and gemcitabine did not result in superior clinical outcomes over weekly docetaxel. Copyright 2009 S. Karger AG, Basel.

Page last updated: 2009-10-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017